JaxBio
Tel Aviv, Israel· Est.
AI‑powered cfDNA blood test for early, multi‑cancer detection.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
AI‑powered cfDNA blood test for early, multi‑cancer detection.
Oncology
Technology Platform
Proprietary cfDNA profiling using a custom microarray chip to capture epigenetic pixel patterns, combined with AI algorithms to select disease‑specific biomarker panels.
Opportunities
Successful validation could unlock large‑scale screening contracts with national health systems and create a platform for expanding to additional cancer types.
Risk Factors
Regulatory approval, clinical validation, and competition from established liquid‑biopsy players could delay market entry.
Competitive Landscape
Competes with Guardant Health, Grail, and Freenome; differentiation lies in epigenetic pixel‑pattern mapping and a potentially lower‑cost chip‑based assay.